GlaxoSmithKline chooses not to exercise right to MET/RET/VEGFR2 inhibitor XL184

GlaxoSmithKline has decided not to exercise its option to license MET/RET/VEGFR2 inhibitor from Exelixis

Exelixis PI3K Inhibitor XL147 effective in Phase I

Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis PI3K inhibitor XL147 to exhibit ‘robust pharmacodynamics’ and preliminary clinical benefit

Exelixis PI3K/mTOR Inhibitor XL765 effective in Phase I

Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis PI3K/mTOR kinase inhbitor XL765  to show  demonstrate ‘robust pharmacodymanics’

Exelixis Raf kinase inhibitor XL281 effective in Phase I

Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis RAF kinase inhbitor XL281 to show early signs of clinical activity

Exelixis IGF-1R/Src inhibitor XL228 effective in Phase I

Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis’ IGF-1R/Src inhibitor  XL228 to show signs of Clinical Benefit inpatients with advanced malignancies

Exelixis MET/VEGFR2/RET inhibitor XL184 effective in Phase I

Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis MET/VEGFR2/RET inhbitor XL184 demonstrates a 55% Response Rate and 84% Disease Control Rate in Patients with Medullary Thyroid Cancer

Exelixis Submit Due Diligence Report for Cdc7 Inhibitor XL413 to BMS

Exelixis has submitted data to BMS on CDC7 inhibitor XL413. BMS has 30 days to decide whether it wants to select the compound for clinical development and commercialization.

Exelixis MET/RET/VEGFR2 inhibitor XL184 achieves proof of concept in cancer

Exelixis have announced that its MET/RET/VEGFR2 inhibitor XL184 has achieved proof of concept in hematologic cancers. The company has submitted data to its partner GSK who has 90 days to review the data and decide whether to exercise its option to select the compound for further development and commercialization.

Exelixis initiate Phase III trial of MET/RET/VEGFR2 inhibitor XL184 in Thyroid cancer

Exelixis have initiated a phase III trial of MET/RET/VEGFR2 inhibitor XL184 for the treatment of medullary thyroid cancer.

Exelixis and GlaxoSmithKline Conclude Six-Year Discovery and Development Collaboration

Exelixis and GlaxoSmithKline will conclude their six-year collaboration in October 2008. GSK will have the right to choose one of the following compounds for for further development and commercialization: XL184, XL281, XL228, XL820, and XL844. GSK previously selected XL880 from the collaboration